T. Rowe Price Investment Management

Funding rounds backed by T. Rowe Price Investment Management.

Export CSV
Funding disclosed in full
$1.2B
Median round
$293.5M
Rounds in calculation
4
4 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries BBiotechUnited States
10 participantsa16z Bio+HealthARCH Venture PartnersBlackstone Multi-Asset InvestingCanada Pension Plan Investment BoardCommodore CapitalMonograph CapitalMubadala CapitalRA Capital ManagementTCGXT. Rowe Price Investment Management
SiFive

Develops RISC-V processor IP for customizable and energy-efficient computing solutions

$400MSeries GHardwareUnited States
7 participantsApollo Global ManagementAtreides ManagementNVIDIAPoint72 TurionProsperity7 VenturesSutter Hill VenturesT. Rowe Price Investment Management
Cellares

Develops automated cell therapy manufacturing platforms

$257MSeries DBiotechUnited States
11 participantsBaillie GiffordBlackRockDC Global VenturesDFJ GrowthDuquesne Family OfficeEclipseEDBIGates FrontierIntuitive VenturesT. Rowe Price Investment ManagementWillett Advisors
Mirador Therapeutics

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries BBiotechUnited States
17 participantsAdage Capital Partners L.P.ARCH Venture PartnersBlue Owl Healthcare OpportunitiesBoxer CapitalFairmountFarallon Capital ManagementFidelity Management & Research CompanyInc.InvusLogos CapitalMoore Strategic VenturesOrbiMedPoint72TCGXT. Rowe Price Investment ManagementVenrock Healthcare Capital PartnersWoodline Partners LP